CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
XF-73 nasal gel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02282605
NCT02282605Phase 2Completed

A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.

Destiny Pharma Plc·interventional·Posted Nov 4, 2014·Updated Oct 7, 2016

In Brief

A Phase 2 clinical trial evaluating XF-73 nasal gel, Placebo nasal gel, and 1 other intervention for Staphylococcus Aureus Infection. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus aureus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 4, 2014
Enrollment StartSep 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.7 years ago

Interventions

XF-73 nasal geldrug

Placebo nasal geldrug

Chlorhexidine gluconate 2% topical clothsother